Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of Chicago Medical Center
Chicago, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of Chicago Medical Center (9)
2022
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
2021
2020
-
First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317
-
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
The Lancet, Vol. 395, Núm. 10218, pp. 132-141
2019
-
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 5, pp. 421-431
2018
-
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528
2017
-
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413
-
Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)
Annals of Translational Medicine, Vol. 5, Núm. 19
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine